Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.24.2.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
6 Months Ended
Jun. 30, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended June 30, 

Six-Month Periods Ended June 30, 

($ in thousands)

    

2024

    

2023

    

2024

    

2023

Qbrexza®

$

6,836

$

8,079

$

11,853

$

12,173

Accutane®

 

5,719

 

5,579

 

11,538

 

10,227

Amzeeq®

1,205

1,374

1,960

2,568

Zilxi®

369

572

642

886

Other / legacy

726

1,357

1,892

3,272

Total product revenues

$

14,855

$

16,961

$

27,885

$

29,126

Schedule of other revenue

    

Three-Month Periods Ended June 30,

    

Six-Month Periods Ended June 30,

($in thousands)

2024

    

2023

2024

    

2023

Other revenue

 

 

211

 

 

259

Total other revenue

$

$

211

$

$

259